Literature DB >> 12744813

The case for uricase in gout.

Salih Pay, And Robert Terkeltaub.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12744813     DOI： 10.1007/s11926-003-0069-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  5 in total

1.  European experience in the treatment of hyperuricemia.

Authors:  C Patte; O Sakiroglu; D Sommelet
Journal:  Semin Hematol       Date:  2001-10       Impact factor: 3.851

2.  Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.

Authors:  C H Pui; H H Mahmoud; J M Wiley; G M Woods; G Leverger; B Camitta; C Hastings; S M Blaney; M V Relling; G H Reaman
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

3.  Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.

Authors:  C H Pui
Journal:  Semin Hematol       Date:  2001-10       Impact factor: 3.851

Review 4.  Pegylation: engineering improved pharmaceuticals for enhanced therapy.

Authors:  G Molineux
Journal:  Cancer Treat Rev       Date:  2002-04       Impact factor: 12.111

5.  Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases.

Authors:  S Rozenberg; B Roche; R Dorent; A C Koeger; C Borget; N Wrona; P Bourgeois
Journal:  Rev Rhum Engl Ed       Date:  1995-05
  5 in total
  1 in total

Review 1.  Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.

Authors:  John S Bomalaski; Mike A Clark
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.